OM
What one share of Outset Medical holds
Electromedical and Electrotherapeutic Apparatus
Outset is a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity. We believe the Tablo® Hemodialysis System (Tablo) represents a significant technological advancement that transforms the dialysis experience for patients and operationally simplifies it for providers.
Outset Medical’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $6.46 |
|---|---|
| Profit | −$4.07 |
| Capex (buildings and equipment) | $0.03 |
| Free cash flow | −$2.13 |
| Cash and investments | $1.86 |
| Debt | $5.29 |
| Book value | $5.13 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | $33.76 | −$43.41 | $1.02 | −$43.88 | — | $118.78 |
| 2022 | $35.93 | −$50.75 | $2.59 | −$47.98 | — | $76.13 |
| 2023 | $39.45 | −$52.28 | $1.04 | −$40.79 | — | $36.63 |
| 2024 | $32.83 | −$36.96 | $0.26 | −$33.85 | — | $7.60 |
| 2025 | $7.85 | −$5.37 | $0.05 | −$3.10 | — | $6.99 |